U.S. Markets closed

Horizon Pharma Public Limited Company (HZNP)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
11.73-0.14 (-1.18%)
At close: 4:00PM EDT
People also watch
DEPOSRPTJUNORDUSFOLD
Full screen
Previous Close11.87
Open11.87
Bid11.20 x 100
Ask15.79 x 100
Day's Range11.49 - 11.93
52 Week Range9.45 - 23.44
Volume8,967,185
Avg. Volume4,580,295
Market Cap1.91B
Beta1.14
PE Ratio (TTM)-8.87
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Horizon Pharma Gets Health Canada Approval for Procysbi
    Zacks4 days ago

    Horizon Pharma Gets Health Canada Approval for Procysbi

    Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

  • Barrons.com8 days ago

    Valeant: Stop Looking in the Rearview Mirror!

    Shares of specialty pharmaceutical companies, including Valeant Pharmaceuticals International (VRX), Horizon Pharma (HZNP), Perrigo (PRGO), and Mallinckrodt (MNK), have been under pressure for a while now, as investors have remained focused on their business models of raising prices. In offering her upbeat view on specialty-pharmaceutical companies, Chen recommends investors to not "look back, because objects in the rearview mirror can appear closer than they are." In fact, she claims that management has already started to pivot from the old model of constantly rising prices, and the ones that can "innovate and/or save the healthcare system money can thrive under the new order." Chen initiated coverage on Aclaris Therapeutics (ACRS), Horizon Pharma, Impax Laboratories (IPXL), Mallinckrodt, Perrigo, Theravance Biopharma (TBPH), Valeant, Zoetis (ZTS), and Shire (SHPG), which she calls her "highest conviction recommendation.

  • Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?
    Zacks12 days ago

    Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?

    Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.